MinXray Affirms Quality of Its Medical Devices with ISO Certification

New Market Requirements Inspire ISO13485:2016 Certification

As healthcare industries begin to require International Organization for Standardization (ISO) certification from their medical device manufacturers, MinXray Inc., a key global supplier of portable, compact digital imaging equipment, announced that it earned ISO13485:2016 Certification on April 21, 2022.

The certification ensures compliance with internationally recognized best practices and safety protocols.

ISO 13485 is a Quality Management System for medical device/component manufacturers. This includes any organization that designs, produces, installs, or services medical devices and components. As a globally recognized standard, ISO 13485:2016 makes product conformity possible amidst expanding international supply chains.

Due to the vital nature of these products, conformity is paramount for reducing risk and increasing customer satisfaction. To earn the certificate, MinXray had to demonstrate to a third-party registrar via certification audit that its quality assurance processes consistently provide devices that meet both customer requests and applicable regulatory requirements.

MinXray’s Director of Technical and Customer Support, Ed Dubbs, commented that MinXray was already doing well before the audit, saying, “We had the details and data required to document adherence to regulatory codes. The audit and subsequent certification gave us added insight into our company’s conformance.”

Moving forward, MinXray’s certification will help its business stand out and grow in the industries that require ISO compliance. MinXray continues to see development internally as well, with Dubbs stating, “The challenge now is to keep MinXray focused on what we do well while being mindful of our deeper understanding of who we are and how we can be better.”


Other diagnostic imaging news can be found here.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.